At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 72 enrolled
Drug / intervention
Nivolumab +2 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Risk-based, Response-adapted, Phase II Open-label Trial of Nivolumab + Brentuximab Vedotin (N + Bv) for Children, Adolescents, and Young Adults With Relapsed/Refractory (R/R) CD30 + Classic Hodgkin Lymphoma (cHL) After Failure of First-line Therapy, Followed by Brentuximab + Bendamustine (Bv + B) for Participants With a Suboptimal Response (CheckMate 744: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation)
In Brief
A Phase 2 clinical trial evaluating Nivolumab, brentuximab vedotin, and 1 other intervention for Hodgkin Disease. Completed, enrolled 72 participants across 79 sites in 11 countries.
Detailed Summary
The purpose of this study is to determine whether nivolumab plus brentuximab vedotin (followed by brentuximab vedotin plus bendamustine in patient with suboptimal response) is safe and effective in treating patients with Hodgkin's lymphoma (cHL). Eligible patients are children, adolescents, and young adults relapsed or refractory to first line.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHodgkin Disease
CountriesCanada, Czechia, France, Germany, Ireland, Italy, Netherlands, Poland, Spain, United Kingdom, United States
CollaboratorsSeagen Inc.
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedOct 2016
Enrollment StartMar 2017
Primary CompletionMay 2024
TodayJul 2026
First PostedOct 7, 2016
Enrollment StartMar 28, 2017
Primary CompletionMay 28, 2024
TodayJul 2, 2026
Enrollment to primary: 7.2 yearsPosted 9.7 years ago
Interventions
Nivolumabbiological
Specified Dose on Specified Days
brentuximab vedotinbiological
Specified Dose on Specified Days
bendamustinebiological
Specified Dose on Specified Days